Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia

G. Vigano, F. Gaspari, M. Locatelli, F. Pusineri, M. Bonati, G. Remuzzi

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Conjugated estrogens have a significant and long-lasting effect in shortening bleeding time in patients with end-stage renal disease. The studies so far available indicate that repeated estrogen administrations are necessary to short bleeding time in uremia in a dose range of 95 to 325 mg. With the present study we wanted to establish whether single or repeated doses are required to induce a significant shortening of bleeding time in uremia, and the minimum cumulative dose of conjugated estrogens necessary to control bleeding time for a prolonged period of time, and to check whether the prolonged effect of estrogens on bleeding time in uremia is due to an accumulation of the drug or its metabolites in the blood. Fifteen uremics on chronic hemodialysis were studied. A pilot study carried out in five uremic patients indicated that single or repeated estrogen infusions of 0.3 mg/kg did not significantly influence bleeding time values. Therefore the subsequent studies have been carried out using daily infusion of 0.6 mg/kg. A single estrogen infusion of 0.6 mg/kg shortened bleeding time in all patients. The effect was transient and bleeding time returned to pre-infusion values within 72 hours. A 50% decrease of bleeding time or a shortening of bleeding time more than 30 to 15 minutes or less was obtained in all patients with four or five infusions (0.6 mg/kg) spaced 24 hours apart. The effect lasted for 14 days. At day 25 from the last infusion all the patients had bleeding time values comparable with the pre-infusion ones. Pharmacokinetic parameters of both estrone sulfate and equilin sulfate, the major components of the estrogen mixture we used, were comparable in both controls and uremics and can be described assuming a two compartmental model. After repeated administrations of conjugated estrogens no accumulation of estrone sulfate and equilin sulfate or their metabolites was detectable in blood in both uremics and controls.

Original languageEnglish
Pages (from-to)853-858
Number of pages6
JournalKidney International
Volume34
Issue number6
Publication statusPublished - 1988

Fingerprint

Bleeding Time
Uremia
Estrogens
Pharmacokinetics
Conjugated (USP) Estrogens
Chronic Kidney Failure
Renal Dialysis

ASJC Scopus subject areas

  • Nephrology

Cite this

Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. / Vigano, G.; Gaspari, F.; Locatelli, M.; Pusineri, F.; Bonati, M.; Remuzzi, G.

In: Kidney International, Vol. 34, No. 6, 1988, p. 853-858.

Research output: Contribution to journalArticle

@article{7bd9deeedeb94492bdbb47c0a235ecc6,
title = "Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia",
abstract = "Conjugated estrogens have a significant and long-lasting effect in shortening bleeding time in patients with end-stage renal disease. The studies so far available indicate that repeated estrogen administrations are necessary to short bleeding time in uremia in a dose range of 95 to 325 mg. With the present study we wanted to establish whether single or repeated doses are required to induce a significant shortening of bleeding time in uremia, and the minimum cumulative dose of conjugated estrogens necessary to control bleeding time for a prolonged period of time, and to check whether the prolonged effect of estrogens on bleeding time in uremia is due to an accumulation of the drug or its metabolites in the blood. Fifteen uremics on chronic hemodialysis were studied. A pilot study carried out in five uremic patients indicated that single or repeated estrogen infusions of 0.3 mg/kg did not significantly influence bleeding time values. Therefore the subsequent studies have been carried out using daily infusion of 0.6 mg/kg. A single estrogen infusion of 0.6 mg/kg shortened bleeding time in all patients. The effect was transient and bleeding time returned to pre-infusion values within 72 hours. A 50{\%} decrease of bleeding time or a shortening of bleeding time more than 30 to 15 minutes or less was obtained in all patients with four or five infusions (0.6 mg/kg) spaced 24 hours apart. The effect lasted for 14 days. At day 25 from the last infusion all the patients had bleeding time values comparable with the pre-infusion ones. Pharmacokinetic parameters of both estrone sulfate and equilin sulfate, the major components of the estrogen mixture we used, were comparable in both controls and uremics and can be described assuming a two compartmental model. After repeated administrations of conjugated estrogens no accumulation of estrone sulfate and equilin sulfate or their metabolites was detectable in blood in both uremics and controls.",
author = "G. Vigano and F. Gaspari and M. Locatelli and F. Pusineri and M. Bonati and G. Remuzzi",
year = "1988",
language = "English",
volume = "34",
pages = "853--858",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia

AU - Vigano, G.

AU - Gaspari, F.

AU - Locatelli, M.

AU - Pusineri, F.

AU - Bonati, M.

AU - Remuzzi, G.

PY - 1988

Y1 - 1988

N2 - Conjugated estrogens have a significant and long-lasting effect in shortening bleeding time in patients with end-stage renal disease. The studies so far available indicate that repeated estrogen administrations are necessary to short bleeding time in uremia in a dose range of 95 to 325 mg. With the present study we wanted to establish whether single or repeated doses are required to induce a significant shortening of bleeding time in uremia, and the minimum cumulative dose of conjugated estrogens necessary to control bleeding time for a prolonged period of time, and to check whether the prolonged effect of estrogens on bleeding time in uremia is due to an accumulation of the drug or its metabolites in the blood. Fifteen uremics on chronic hemodialysis were studied. A pilot study carried out in five uremic patients indicated that single or repeated estrogen infusions of 0.3 mg/kg did not significantly influence bleeding time values. Therefore the subsequent studies have been carried out using daily infusion of 0.6 mg/kg. A single estrogen infusion of 0.6 mg/kg shortened bleeding time in all patients. The effect was transient and bleeding time returned to pre-infusion values within 72 hours. A 50% decrease of bleeding time or a shortening of bleeding time more than 30 to 15 minutes or less was obtained in all patients with four or five infusions (0.6 mg/kg) spaced 24 hours apart. The effect lasted for 14 days. At day 25 from the last infusion all the patients had bleeding time values comparable with the pre-infusion ones. Pharmacokinetic parameters of both estrone sulfate and equilin sulfate, the major components of the estrogen mixture we used, were comparable in both controls and uremics and can be described assuming a two compartmental model. After repeated administrations of conjugated estrogens no accumulation of estrone sulfate and equilin sulfate or their metabolites was detectable in blood in both uremics and controls.

AB - Conjugated estrogens have a significant and long-lasting effect in shortening bleeding time in patients with end-stage renal disease. The studies so far available indicate that repeated estrogen administrations are necessary to short bleeding time in uremia in a dose range of 95 to 325 mg. With the present study we wanted to establish whether single or repeated doses are required to induce a significant shortening of bleeding time in uremia, and the minimum cumulative dose of conjugated estrogens necessary to control bleeding time for a prolonged period of time, and to check whether the prolonged effect of estrogens on bleeding time in uremia is due to an accumulation of the drug or its metabolites in the blood. Fifteen uremics on chronic hemodialysis were studied. A pilot study carried out in five uremic patients indicated that single or repeated estrogen infusions of 0.3 mg/kg did not significantly influence bleeding time values. Therefore the subsequent studies have been carried out using daily infusion of 0.6 mg/kg. A single estrogen infusion of 0.6 mg/kg shortened bleeding time in all patients. The effect was transient and bleeding time returned to pre-infusion values within 72 hours. A 50% decrease of bleeding time or a shortening of bleeding time more than 30 to 15 minutes or less was obtained in all patients with four or five infusions (0.6 mg/kg) spaced 24 hours apart. The effect lasted for 14 days. At day 25 from the last infusion all the patients had bleeding time values comparable with the pre-infusion ones. Pharmacokinetic parameters of both estrone sulfate and equilin sulfate, the major components of the estrogen mixture we used, were comparable in both controls and uremics and can be described assuming a two compartmental model. After repeated administrations of conjugated estrogens no accumulation of estrone sulfate and equilin sulfate or their metabolites was detectable in blood in both uremics and controls.

UR - http://www.scopus.com/inward/record.url?scp=0024239325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024239325&partnerID=8YFLogxK

M3 - Article

C2 - 2850395

AN - SCOPUS:0024239325

VL - 34

SP - 853

EP - 858

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -